BCR pathway inhibitors idelalisib and ibrutinib were the first small molecule targeted agents for B-cell malignancies. In spite of encouraging response rates in various forms of B cell diseases, patients will eventually develop relapse due to the emergence of resistant cells. To better identify the possible mechanisms of resistance we developed and characterized idelalisib-and ibrutinib-resistant variants of the human non Hodgkin's lymphoma cell lines DoHH2 and Daudi. These resistant variants displayed a cross-resistance profile limited to PI3K inhibitors, BTK inhibitors and a SYK inhibitor but not to unrelated agents. A number of alterations were observed in the resistant lines, including a strong reduction of BLINK and the AKT3. A new SNP in PLCgamma2 (Leu848Phe) closely related to a previously reported SNP associated to ibrutinib resistance (Leu845Phe) was observed in both DAUDI-based resistant cell lines but was absent in wild type cells. Resistant lines tended to express larger amounts of CD38 and were found to display enhanced sensitivity to anti-CD38 antibodies.
Introduction
The introduction of small molecule kinase inhibitors has deeply modified the treatment of patients with lymphoproliferative diseases [1] . Idelalisib, an oral reversible phosphoinositide-3 kinase (PI3K) p110δ inhibitor and ibrutinib, an oral irreversible inhibitor of Bruton's Tyrosine Kinase (BTK) are both approved in certain indications of lymphoid malignancies [2] . Despite the initial efficacy of these drugs in a majority of cases, some patients relapse during treatment or fail to respond to single agent therapy, prompting the development of combination regimens [3, 4] . It is therefore necessary to better understand mechanisms of resistance to these agents [5] .
Resistance to small molecule targeted therapies is commonly due to alterations in the target molecule.
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib have been reported to involve mutations of the binding site of ibrubinib to BTK, potential gain of function mutations of PLCgamma2 and activation of MYC [6, 7] . In the case of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib acquired mutations of BTK or PLCG2 were found in up to 85% (95% CI, 71% to 94%) of CLL patients who relapsed under therapy [8] . SWI-SNF mutations have been shown to mediate resistance to ibrutinib and venetoclax in mantle cells lymphoma [9] .
Resistance to idelalisib has been linked to PIK3 and Myc amplification [10] .
Material and Methods

Cell lines and cytotoxicity assays
Cell lines used were the Burkitt lymphoma line DAUDI, and the follicular lymphoma line DOHH2 (both obtained from ATCC). They were made resistant to idelalisib (=idela-R) or ibrutinib (=ibru-R) by exposing the cells to increasing drug concentrations over several months. In the case of idelalisib Daudi was exposed from 1.3 µM up to a final concentration of 16 µM while DoHH2 was exposed from 2.4 µM up to 15 µM. For ibrutinib resistant variants Daudi was exposed from 0.13 µM to a final concentration of 4 µM while DoHH2 was exposed from 0.04 µM up to 0.6 µM. The half maximal inhibitory concentration (IC 50 ) of several drugs was obtained using MTT assay, as previously described [11] .
RT-PCR
Total RNA was extracted from cell suspensions and 2 µg of mRNA was reverse transcribed. PCR was performed on LC480 LightCycler® Nano in triplicate. Data were calculated using the ∆Ct method with ribosomal 28S RNA as endogenous control.
Western blotting
Proteins were extracted using a RIPA lysis buffer.
Antibodies used were anti-total AKT (Cell Signaling, ref: 
Flow cytometry analysis
Results and Discussion
Resistant variants are specifically resistant to BCR pathway inhibitors
Resistance to therapy is usually multifactorial. Yahiaoui shown that P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma [14] . Kuo et al. [15] reported point mutations within the kinase PIM1 that reduce sensitivity to ibrutinib in ABC-DLBCL [15] .
Remarkably our ibrutinib-and idelalisib-resistant variants displayed high levels of cross-resistance to BCR-pathway inhibitors but not to agents with unrelated mechanisms of action ( Figure 1A ). Variants were cross-resistant to the two PI3K inhibitors idelalisib and duvelisib, the two BTK Figure 1C) while total AKT and Akt1 were present at similar contents in sensitive and resistant lines. Akt3 has been reported to suppress Aurora kinase induced apoptosis and conferred resistance to polo-like kinase inhibitors [16, 17] . Conversely Akt3 was found to be associated with slower disease progression in glioblastoma, as opposed to Akt1 and Akt2 [18] . Exposure of Waldenström's cell lines to the AKT inhibitor MK2206 and ibrutinib was found to be synergistic [19] . Fifteen SNPs with missense mutations were found on expressed genes involved in the BCR pathway (hsa05220), but no premature stop codon nor frameshift mutation in coding sequences were identified (Supplemental Table 1 ). (Figure   2A ). Variants were exposed to daratumumab and isatuximab and were found to undergo enhanced apoptosis in comparison to parental cells ( Figure 2B ). It would be worthwhile to determine whether the enhancement of CD38
SNPs previously reported on BTK and
is also observed in the tumor microenvironment since CD38 targeting has been proposed as a possible means to reduce local immunosuppression [20] .
These in vitro models of resistance to BCR inhibitors suggest novel mechanisms of resistance and have identified enhanced CD38 expression as a possible therapeutic target to be explored and validated in patients with resistant disease. 
